论文部分内容阅读
传统的三环类抗抑郁药（TCA）和单胺氧化酶抑制剂（MAOI）常引起许多不良反应，如镇静、失眠、体位性低血压、尿潴留、恶心、呕吐及与食物的相互作用。理想的新型抗抑郁药疗效应与当前使用的药物相当，且无因不良反应而导致的不顺从用药问题。venlafaxine在抗抑郁作用方面与TCA，MAOI，选择性5－HT重摄取抑制剂相当，但其抗胆碱能、肾上腺素能和组胺能的不良反应轻微，因此美国食品和药品管理局（FDA）已正式批准投放市场。本文对venlafaxine的药理学、药效学、药动学、临床应用研究及其安全性和不良反应进行了介绍。
Traditional tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) often cause many side effects such as sedation, insomnia, orthostatic hypotension, urinary retention, nausea, vomiting and food-borne interactions. The ideal new antidepressant effect is comparable to currently used medications, with no problems with objectionable medication due to adverse effects. Venlafaxine is comparable in antidepressant activity to TCA, MAOI, and selective 5-HT reuptake inhibitors, but its anticholinergic, adrenergic, and histaminergic adverse effects are mild, and therefore the U.S. Food and Drug Administration ) Has been officially approved to market. This article describes the pharmacology, pharmacodynamics, pharmacokinetics, clinical application of venlafaxine and its safety and adverse reactions.